References
- Iwase A, Suzuki Y, Araie M, Yamamoto T, Abe H, Shirato S, Kuwayama Y, Mishima HK, Shimizu H, Tomita G. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi study. Ophthalmology. 2004;111(9):1641–48. doi:https://doi.org/10.1016/j.ophtha.2004.03.029.
- Coleman AL, Miglior S. Risk factors for glaucoma onset and progression. Surv Ophthalmol. 2008;53(Suppl1):S3–10. doi:https://doi.org/10.1016/j.survophthal.2008.08.006.
- Sakamoto M, Kitamura K, Kashiwagi K. Changes in glaucoma medication during the past eight years and future directions in Japan based on an insurance medical claim database. J Ophthalmol. 2017;2017:7642049. doi:https://doi.org/10.1155/2017/7642049.
- Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–90. doi:https://doi.org/10.1016/j.ophtha.2014.05.013.
- Distelhorst JS, Hughes GM. Open-angle glaucoma. Am Fam Physician. 2003;67:1937–44.
- Rein DB, Zhang P, Wirth KE, Lee PP, Hoerger TJ, McCall N, Klein R, Tielsch JM, Vijan S, Saaddine J. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol. 2006;124(12):1754–60. doi:https://doi.org/10.1001/archopht.124.12.1754.
- Kobelt-Nguyen G, Gerdtham UG, Alm A. Costs of treating primary open-angle glaucoma and ocular hypertension: a retrospective, observational two-year chart review of newly diagnosed patients in Sweden and the United States. J Glaucoma. 1998;7(2):95–104. doi:https://doi.org/10.1097/00061198-199804000-00006.
- Traverso CE, Walt JG, Kelly SP, Hommer AH, Bron AM, Denis P, Nordmann JP, Renard JP, Bayer A, Grehn F, et al. Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe. Br J Ophthalmol. 2005;89(10):1245–49. doi:https://doi.org/10.1136/bjo.2005.067355.
- Ocansey S, Kyei S, Diafo A, Darfor KN, Boadi-Kusi SB, Aglobitse PB. Cost of the medical management and prescription pattern for primary open angle glaucoma (POAG) in Ghana-a retrospective cross-sectional study from three referral facilities. BMC Health Serv Res. 2016;16:e282. doi:https://doi.org/10.1186/s12913-016-1528-x.
- Iskedjian M, Walker J, Vicente C, Trope GE, Buys Y, Einarson TR, Covert D. Cost of glaucoma in Canada: analyses based on visual field and physician’s assessment. J Glaucoma. 2003;12(6):456–62. doi:https://doi.org/10.1097/00061198-200312000-00002.
- Rylander NR, Vold SD. Cost analysis of glaucoma medications. Am J Ophthalmol. 2008;145(1):106–13. doi:https://doi.org/10.1016/j.ajo.2007.08.041.
- Stewart WC, Stewart JA, Mychaskiw MA. Cost-effectiveness of latanoprost and timolol maleate for the treatment of glaucoma in Scandinavia and the United Kingdom, using a decision-analytic health economic model. Eye (Lond). 2009;23(1):132–40. doi:https://doi.org/10.1038/sj.eye.6702964.
- Kaplan RI, De Moraes CG, Cioffi GA, Al-Aswad LA, Blumberg DM. Comparative cost-effectiveness of the baerveldt implant, trabeculectomy with mitomycin, and medical treatment. JAMA Ophthalmol. 2015;133(5):560–67. doi:https://doi.org/10.1001/jamaophthalmol.2015.44.
- Omoti AE, Edema OT, Akpe BA, Musa P. Cost analysis of medical versus surgical management of glaucoma in Nigeria. J Ophthalmic Vis Res. 2010;5:232–39.
- Kimura S, Sato T, Ikeda S, Noda M, Nakayama T. Development of a database of health insurance claims: standardization of disease classifications and anonymous record linkage. J Epidemiol. 2010;20(5):413–19. doi:https://doi.org/10.2188/jea.JE20090066.
- Kashiwagi K. Changes in trend of newly prescribed anti-glaucoma medications in recent nine years in a Japanese local community. Open Ophthalmol J. 2010;4:7–11. doi:https://doi.org/10.2174/1874364101004010007.
- Kashiwagi K, Chiba T, Mabuchi F, Furuya T, Tsukahara S. Five-year incidence of angle closure among glaucoma health examination participants. Graefes Arch Clin Exp Ophthalmol. 2013;251(4):1219–28. doi:https://doi.org/10.1007/s00417-012-2179-1.
- Kume A, Ohshiro T, Sakurada Y, Kikushima W, Yoneyama S, Kashiwagi K. Treatment patterns and health care costs for age-related macular degeneration in Japan: an analysis of national insurance claims data. Ophthalmology. 2016;123(6):1263–68. doi:https://doi.org/10.1016/j.ophtha.2016.01.042.
- Nordmann JP, Lafuma A, Deschaseaux C, Berdeaux G. Clinical outcomes of glaucoma treatments over a patient lifetime: a Markov model. J Glaucoma. 2005;14(6):463–69. doi:https://doi.org/10.1097/01.ijg.0000184834.93535.0b.
- Lee PP, Walt JG, Doyle JJ, Kotak SV, Evans SJ, Budenz DL, Chen PP, Coleman AL, Feldman RM, Jampel HD, et al. A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma. Arch Ophthalmol. 2006;124(1):12–19. doi:https://doi.org/10.1001/archopht.124.1.12.
- Guedes RA, Guedes VM, Gomes CE, Chaoubah A. Maximizing cost-effectiveness by adjusting treatment strategy according to glaucoma severity. Medicine (Baltimore). 2016;95(52):e5745. doi:https://doi.org/10.1097/MD.0000000000005745.
- Burr J, Azuara-Blanco A, Avenell A, Tuulonen A. Medical versus surgical interventions for open angle glaucoma. Cochrane Database Syst Rev. 2012;9:CD004399.
- Sherwood MB, Migdal CS, Hitchings RA, Sharir M, Zimmerman TJ, Schultz JS. Initial treatment of glaucoma: surgery or medications. Surv Ophthalmol. 1993;37(4):293–305. doi:https://doi.org/10.1016/0039-6257(93)90013-W.
- Lichter PR, Musch DC, Gillespie BW, Guire KE, Janz NK, Wren PA, Rp M. Interim clinical outcomes in the collaborative initial glaucoma treatment study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108(11):1943–53. doi:https://doi.org/10.1016/S0161-6420(01)00873-9.
- Okeke CO, Quigley HA, Jampel HD, Ying GS, Plyler RJ, Jiang Y, Friedman DS. Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study. Ophthalmology. 2009;116(2):191–99. doi:https://doi.org/10.1016/j.ophtha.2008.09.004.
- Friedman DS, Quigley HA, Gelb L, Tan J, Margolis J, Shah SN, Kim EE, Zimmerman T, Hahn SR. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS). Invest Ophthalmol Vis Sci. 2007;48(11):5052–57. doi:https://doi.org/10.1167/iovs.07-0290.
- Tsumura T, Kashiwagi K, Suzuki Y, Yoshikawa K, Suzumura H, Maeda T, Takeda R, Saito H, Araie M. A nationwide survey of factors influencing adherence to ocular hypotensive eyedrops in Japan. Int Ophthalmol. 2019;39(2):375–83. doi:https://doi.org/10.1007/s10792-018-0820-7.
- Hennessy AL, Katz J, Covert D, Protzko C, Robin AL. Videotaped evaluation of eyedrop instillation in glaucoma patients with visual impairment or moderate to severe visual field loss. Ophthalmology. 2010;117(12):2345–52. doi:https://doi.org/10.1016/j.ophtha.2010.03.040.
- King AJ, Fernie G, Azuara-Blanco A, Burr JM, Garway-Heath T, Sparrow JM, Vale L, Hudson J, MacLennan G, McDonald A, et al. Treatment of advanced glaucoma study: a multicentre randomised controlled trial comparing primary medical treatment with primary trabeculectomy for people with newly diagnosed advanced glaucoma-study protocol. Br J Ophthalmol. 2018;102(7):922–28. doi:https://doi.org/10.1136/bjophthalmol-2017-310902.
- Konstantakopoulou E, Gazzard G, Vickerstaff V, Jiang Y, Nathwani N, Hunter R, Ambler G, Bunce C. The laser in glaucoma and ocular hypertension (LiGHT) trial. A multicentre randomised controlled trial: baseline patient characteristics. Br J Ophthalmol. 2018;102(5):599–603. doi:https://doi.org/10.1136/bjophthalmol-2017-310870.